ATC Group: A16AA Amino acids and derivatives

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A16AA in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A16 Other alimentary tract and metabolism products
3 A16A Other alimentary tract and metabolism products
4 A16AA Amino acids and derivatives

Group A16AA contents

Code Title
A16AA01 Levocarnitine
A16AA02 Ademetionine
A16AA03 Glutamine
A16AA04 Mercaptamine
A16AA05 Carglumic acid
A16AA06 Betaine
A16AA07

Active ingredients in A16AA

Active Ingredient Description
Ademetionine

Ademetionine is a naturally occurring amino acid present in virtually all body tissues and fluids. Ademetionine functions primarily as a co-enzyme and donor transfer of the methyl group (transmethylation) is an essential metabolic process in humans and animals. Ademetionine is also a precursor in the formation of physiological sulfurated compounds (cysteine, taurine, glutathione, CoA, etc.) via transsulfuration. It is used for the treatment of intrahepatic cholestasis.

Betaine

Betaine anhydrous was shown to lower plasma homocysteine levels in the three types of homocystinuria, i.e. CBS deficiency; MTHFR deficiency and cbl defect. The extent of this effect was dependent on the absolute degree of hyperhomocysteinemia, being higher in severe hyperhomocysteinemia. Betaine anhydrous acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with homocystinuria.

Carglumic acid

Carglumic acid is a carbamoyl phosphate synthetase 1 (CPS 1) allosteric modulator. CPS1 is found in the mitochondria and is the first enzyme of the urea cycle, which converts ammonia into urea. Carglumic acid acts as a replacement for N-acetylglutamate (NAG) in N-acetylglutamate synthase (NAGS) deficiency patients by activating CPS1 but it does not help to regulate the urea cycle. Carglumic acid indicated as adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme NAGS.

Glutamine
L-carnitine

Levocarnitine as a factor is necessary in the transport of long-chain fatty acids into the mitochondria-facilitating the oxidation of fatty acids rather than their incorporation into triglycerides.

Mercaptamine

Mercaptamine reduces corneal cystine crystal accumulation acting as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides.

Metreleptin

Metreleptin mimics the physiological effects of leptin by binding to and activating the human leptin receptor, which belongs to the Class I cytokine family of receptors that signals through the JAK/STAT transduction pathway.

Related product monographs

Title Information Source Document Type  
AMVERSIO Oral powder European Medicines Agency (EU) MPI, EU: SmPC
CARBAGLU Dispersible tablet European Medicines Agency (EU) MPI, EU: SmPC
CARNITOR Tablet / Oral solution FDA, National Drug Code (US) MPI, US: SPL/Old
CYSTADANE Oral powder European Medicines Agency (EU) MPI, EU: SmPC
CYSTADANE Powder for oral solution FDA, National Drug Code (US) MPI, US: SPL/PLR
CYSTAGON Capsule FDA, National Drug Code (US) MPI, US: SPL/Old
CYSTAGON Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
MYALEPTA Powder for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PROCYSBI Capsule / Granules FDA, National Drug Code (US) MPI, US: SPL/PLR
TRANSMETIL Tablet / Powder for solution for injection MPI, EU: SmPC
UCEDANE Dispersible tablet European Medicines Agency (EU) MPI, EU: SmPC